newscontact us

CESCA CLI FEASIBILITY STUDY PUBLISHED IN PEER-REVIEWED JOURNAL

Rancho Cordova, CA, March 20, 2017 — Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the publication in a peer reviewed journal of data from its Critical Limb Ischemia (CLI) feasibility study utilizing the Company’s innovative point-of-care technology. The report was published in the “Stem Cells International” and is available online at https://www.hindawi.com/journals/sci/2017/4137626/ref/…(more)